NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM was delisted on the 4th of April, 2024.
107 hedge funds and large institutions have $849M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 46 increasing their positions, 21 reducing their positions, and 19 closing their positions.
2,957% more call options, than puts
Call options by funds: $642K | Put options by funds: $21K
119% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 21
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
1% less funds holding
Funds holding: 108 → 107 (-1)
5% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 19
32% less capital invested
Capital invested by funds: $1.25B → $849M (-$401M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$22.4M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$11.7M |
| 3 |
JP Morgan Chase
New York
|
+$10.2M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$8.01M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$7.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$30.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$20M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$10.9M |
| 4 |
BlackRock
New York
|
-$10.9M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$10.6M |
NGM Hedge Fund Activity: Q2 2021 in Review
107 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q2 2021, worth a combined $849M — down 32% from $1.25B a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of NGM and 18 opened new positions — a net loss of 1 holder — while 21 trimmed existing stakes and 46 added.
The largest buyer was BVF Inc, opening a new position worth an estimated $22.4M. The largest seller was Point72 Asset Management, cutting an estimated $30.7M.
- 107 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q2 2021, down from 108 in Q1 2021.
- Funds reported $849M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q2 2021, down 32% quarter-over-quarter.
- 18 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q2 2021 and 19 closed out, a net change of -1 holder.
- The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q2 2021 was BVF Inc, an estimated $22.4M added.
- The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q2 2021 was Point72 Asset Management, an estimated $30.7M sold.
Based on aggregated 13F filings for Q2 2021.